What are the mortality statistics for geriatric patients with metastatic prostate cancer?

Mortality Statistics in Geriatric Patients with Metastatic Prostate Cancer

Approximately 70% of all prostate cancer deaths occur in men aged 75 years and older, and these deaths typically occur after a period of metastatic disease. 1

Age-Specific Mortality Distribution

The burden of prostate cancer mortality is heavily concentrated in the geriatric population, with a clear age-dependent pattern:

• Only 1 in 100 prostate cancer deaths occur in men younger than 55 years 1
• Approximately 1 in 20 (5%) prostate cancer deaths occur in men aged 55-64 years 1
• 2 in 10 (20%) prostate cancer deaths occur in men aged 65-74 years 1
• 7 in 10 (70%) prostate cancer deaths occur in men aged 75 years and older 1

Disease Presentation and Outcomes in Older Patients

Geriatric patients present with significantly more advanced disease at diagnosis:

• The frequency of metastatic (M1) disease at presentation increases dramatically with age: 3% for patients <75 years, 5% for ages 75-79 years, 8% for ages 80-84 years, 13% for ages 85-89 years, and 17% for patients ≥90 years 2
• Patients aged ≥75 years represent only 26% of all prostate cancer cases but contribute 48% of all metastatic cases and 53% of all prostate cancer deaths 2

Survival Statistics for Metastatic Disease in Geriatric Patients

The 5-year cumulative incidence of death from prostate cancer increases substantially with age:

• 3-4% for all patients <75 years 2
• 7% for patients aged 75-79 years 2
• 13% for patients aged 80-84 years 2
• 20% for patients aged 85-89 years 2
• 30% for patients aged ≥90 years 2

Contemporary Survival Data for Metastatic Disease

In patients with de novo metastatic prostate cancer treated with androgen deprivation therapy:

• Patients aged ≥80 years have significantly worse cancer-specific survival compared to younger patients (hazard ratio 1.41; 95% CI 1.10-1.80) 3
• However, the 5-year net overall survival (accounting for competing causes of death) in patients aged ≥80 years is comparable to younger patients aged <75 years (0.718 vs 0.678, respectively) 3
• For low-volume metastatic disease, 5-year net overall survival in patients ≥80 years is 0.893, comparable to 0.872 in patients <75 years 3
• For high-volume metastatic disease, 5-year net overall survival drops to 0.586 in both age groups 3

Age as an Independent Prognostic Factor

Age remains an independent predictor of prostate cancer-specific mortality even in the modern treatment era:

• Men aged ≥75 years experience a mean prostate cancer-specific survival at 5 years that is 6.7 months shorter than men aged ≤54 years (95% CI, 5.5-7.8 months) 4
• Men aged ≥75 years have a 49% increase in the rate of prostate cancer-specific mortality compared to those aged ≤54 years (95% CI, 1.39-1.60) 4
• The subdistribution hazard ratio for prostate cancer-specific mortality between these groups is 1.41 (95% CI, 1.32-1.50) 4

Competing Causes of Death

While prostate cancer mortality is substantial in geriatric patients, competing causes of death are also significant:

• Among all patients with metastatic prostate cancer who died, 77.8% died from prostate cancer, 5.5% from other cancers, and 16.7% from non-cancer causes 5
• The most common non-cancer causes of death include cardiovascular diseases (SMR 1.34; 95% CI 1.26-1.42), chronic obstructive pulmonary disease (SMR 1.19; 95% CI 1.03-1.36), and cerebrovascular diseases (SMR 1.31; 95% CI 1.13-1.50) 5

Clinical Context

Despite higher competing mortality risks, older patients with metastatic prostate cancer have a greater absolute risk of dying from their cancer compared to younger patients because they are more likely to present with advanced disease and have higher disease-specific mortality rates. 2 The median age at death from prostate cancer is 78 years. 1